Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study

References

• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–663. doi:10.2165/00003088-200645070-00002
   PubMed Web of Science ®Google Scholar
• Wang T, Sun JY, Chen SY, et al. Population pharmacokinetics study of voriconazole and dosing regimen optimization in patients with invasive fungus infections. Chin Pharm J. 2014;24:227–233.
   Google Scholar
• Boyd AE, Modi S, Howard SJ, et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004;39(8):1241–1244. doi:10.1086/424662
   PubMed Web of Science ®Google Scholar
• Imhof A, Schaer DJ, Schanz U, et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45–46):739–742.
   PubMed Web of Science ®Google Scholar
• Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant. 2012;12(7):1929–1935. doi:10.1111/j.1600-6143.2012.04042.x
   PubMed Web of Science ®Google Scholar
• Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection. 2012;40(6):661–667. doi:10.1007/s15010-012-0322-x
   PubMed Web of Science ®Google Scholar
• Zonios DI, Gea-Banacloche J, Childs R, et al. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47:1. doi:10.1086/588844
   Web of Science ®Google Scholar
• Eiden C, Peyrière H, Cociglio M, et al. Adverse effects of voriconazole: analysis of the French pharmacovigilance database. Ann Pharmacother. 2007;41(5):755–763. doi:10.1345/aph.1H671
   PubMed Web of Science ®Google Scholar
• Dolton MJ, McLachlan AJ. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity. Int J Antimicrob Agents. 2014;44(3):183–193. doi:10.1016/j.ijantimicag.2014.05.019
   Web of Science ®Google Scholar
• Lutsar I, Hodges MR, Tomaszewski K, et al. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36(8):1087–1088. doi:10.1086/374248
   Web of Science ®Google Scholar
• Chu HY, Jain R, Xie H, et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:105. doi:10.1186/1471-2334-13-105
   PubMed Web of Science ®Google Scholar
• Heo ST, Aitken SL, Tverdek FP, et al. How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels? Clin Microbiol Infect. 2017;23(6):387–390. doi:10.1016/j.cmi.2016.12.031
   Web of Science ®Google Scholar
• Koselke E, Kraft S, Smith J, et al. Evaluation of the effect of obesity on voriconazole serum concentrations. J Antimicrob Chemother. 2012;67(12):2957–2962. doi:10.1093/jac/dks312
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:4. doi:10.1093/cid/ciw326
   Web of Science ®Google Scholar
• World Health Organization. The Uppsala monitoring centre. The use of the WHO-UMC system for standardised case causality assessment, 2018; 2020.
   Google Scholar
• Cancer. NIo. Common Terminology Criteria for Adverse Events (CTCAE). Waltham, MA. UpToDate; 2017:1–9.
   Google Scholar
• Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. Int J Antimicrob Agents. 2014;44(5):436–442. doi:10.1016/j.ijantimicag.2014.07.013
   PubMed Web of Science ®Google Scholar
• Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis. 2012;55(3):381–390. doi:10.1093/cid/cis437
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–211. doi:10.1086/524669
   PubMed Web of Science ®Google Scholar
• Hamada Y, Ueda T, Miyazaki Y, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses. 2020;63(8):779–786. doi:10.1111/myc.13129
   PubMed Web of Science ®Google Scholar
• Ashley ESD, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(Supplement_1):S28–S39. doi:10.1086/504492
   Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–547. doi:10.1124/dmd.31.5.540
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–637. doi:10.1086/367933
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–2172. doi:10.1128/AAC.48.6.2166-2172.2004
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Verweij PE, et al. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013;11(9):931–941. doi:10.1586/14787210.2013.826989
   PubMed Web of Science ®Google Scholar
• Mikus G, Scholz IM, Weiss J. Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011;12(6):861–872. doi:10.2217/pgs.11.18
   PubMed Web of Science ®Google Scholar
• Wang G, Lei H-P, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009;65(3):281–285. doi:10.1007/s00228-008-0574-7
   PubMed Web of Science ®Google Scholar
• Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009;49(2):196–204. doi:10.1177/0091270008327537
   PubMed Web of Science ®Google Scholar
• Sienkiewicz B, Urbaniak-Kujda D, Dybko J, et al. Influence of CYP2C19 genotypes on the occurrence of adverse drug reactions of voriconazole among hematological patients after Allo-HSCT. Pathology & Oncology Research. 2018;24(3):541–545. doi:10.1007/s12253-017-0264-9
   Web of Science ®Google Scholar
• Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102(1):45–51. doi:10.1002/cpt.583
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Ikawa K, Abematsu K, et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents. 2009;34(1):91–94. doi:10.1016/j.ijantimicag.2009.01.008
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu MA, Wang Y, et al. Analysis of genetic polymorphisms and metabolic phenotype of CYP2C19 in 604 senile patients with coronary heart disease. J Cardiovasc and Pulmonary Dis. 2015;23: 6186–6192.
   Google Scholar
• Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi:10.1093/jac/dkw045
   PubMed Web of Science ®Google Scholar
• Gómez-López A. Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect. 2020;26(11):1481–1487. doi:10.1016/j.cmi.2020.05.037
   PubMed Web of Science ®Google Scholar
• Xiong W-H, Brown RL, Reed B, et al. Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels. Invest Ophthalmol Vis Sci. 2015;56(2):1367–1373. doi:10.1167/iovs.14-15270
   Web of Science ®Google Scholar